BioCentury
ARTICLE | Product R&D

Nimble move

Nimbus and Celgene go in for TYK and STING

October 5, 2017 10:08 PM UTC

Celgene Corp.’s deal with Nimbus Therapeutics LLC is another vote of confidence that Nimbus’ computational drug design technology can solve druggability problems that trip up standard medicinal chemistry. The partnership gives Celgene access to two promising but problematic autoimmune disease targets: TYK2 and STING.

In the partnership announced Oct. 3, Celgene agreed to pay Nimbus an upfront undisclosed fee to help fund the two programs through clinical proof of concept, at which point Celgene has an option to acquire each program for an additional fee. Nimbus is also eligible for milestones. Financial details are not disclosed...